Antibody drug
Antibody Drug Conjugates: A Leap Ahead in Cancer Treatment
... Antibody drug conjugates comprises of a MAb chemically coupled to a linker and a cytotoxic drug ...intracellular drug release followed by antigen-specific binding and internalization of the ...
8
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
... an antibody -drug immunoconjugate that consists of a humanized monoclonal antibody (M9346A) targeting folate receptor alpha (FRα)-positive cancer cells [4] attached to a highly potent cytotoxic ...
10
Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
... of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great ...an antibody and toxin-drug combined together via a chemical ...the ...
16
Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases
... Recently, antibody-directed chemotherapy has offered a very promising approach to overcome these inherent limitations of systemic chemotherapy by leveraging the targeting capability of antibodies towards ...
16
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
... BV in combination with chemotherapy has been re- ported to optimize the frontline treatment of newly diag- nosed advanced stage HL. This report was from the international randomized phase III trial (ECHELON-1, ...
17
Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate
... Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly overexpressed on the surface of diverse human carcinomas and is an attractive target for the development of mAb-based therapeutics. However, attempts at ...
12
Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection
... clonal antibody (referred to as anti-CD74–011 mAb hereafter) was used as a control for background tissue uptake characteristic of a non-specific IgG clearance mechanism, with known negative organ accumulation and ...
17
Antibody-drug conjugates--an emerging class of cancer treatment.
... Although antibody-drug conjugates (ADCs) have been under investigation for decades, it is only recently with the advent of significant advances in engineering new linker and conjugation technologies ...
6
Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
... of antibody drug conjugates ...per antibody but also result in development of more homogenous ...on antibody reduction. After antibody reduction, the Ellman's test and SDS-PAGE analysis ...
5
Antibody drug conjugate targeting CD46 eliminates multiple myeloma cells
... Multiple myeloma is incurable by standard approaches because of inevitable relapse and development of treatment resistance in all patients. In our prior work, we identified a panel of macropinocytosing human monoclonal ...
15
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
... an antibody-drug conjugate that consists of a humanized anti-CD22 monoclonal antibody linked to a cytotoxic agent cali- cheamicin which can cause double-strand DNA breaks and lead to apoptosis ...
13
MALDI-MS: a Rapid and Reliable Method for Drug-to-Antibody Ratio Determination of Antibody-Drug Conjugates
... anticancer drug conjugated to the monoclonal antibody, called drug-to-antibody ratio (DAR), is the main quality feature of antibody-drug ...related drug-linker, in order ...
9
Tumor stroma–targeted antibody drug conjugate triggers localized anticancer drug release
... ADC tumor response relates to tumor cell MMAE sensitivity and P-gp levels. Because DAaRTS ultimately results in tumor cell killing, we reasoned that inherent sensitivity of tumor cells to MMAE may be a major determinant ...
18
A Pilot Study of Antibody Drug Therapy to Regulate Cell Adhesion in Dental Implants
... In this study, we focused on the structural change in the α 3 chain of laminin- 332 by cleavage of LG domains. We attempted to suppress the biological func- tion using monoclonal antibodies targeting the cleavage sites ...
7
Fate of Antibody-Drug Conjugates in Cancer Cells
... biparatopic antibody, encompassing four target-binding ...monoclonal antibody 39S. This biparatopic antibody was found to be capable to induce the signaling effects issued from the two original ...
12
New antibody approaches to lymphoma therapy
... ADCC: Antibody dependent cellular cytotoxicity; ADC: Antibody drug conjugates; RIT: Radioimmunotherapy; CaRs: Chimeric antigen receptors; BiTEs: Bispecific t-cell engagers; CDC: Complement dependent ...
12
Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
... Abstract: Antibody–drug conjugate (ADC) is a milestone in targeted cancer therapy that comprises of monoclonal antibodies chemically linked to cytotoxic ...
12
Impact Factors in the Process Development for Therapeutic Antibodies
... traditional antibody downstream process has been well developed and is relatively ...monoclonal antibody drug candidate, it is necessary to start the process optimization as early as possible, and it ...
7
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
... With the rapid development of naked monoclonal anti- bodies, antibody-drug conjugates, bispecific T cell enga- gers, and adoptive T cell therapies, the era of R/R ALL treatment is fast forwarding. CD19, ...
13
Microtubule inhibitor-based antibody–drug conjugates for cancer therapy
... of antibody-drug conjugates (ADCs) takes advantage of the specificity of the monoclonal antibody and potent cytotoxic effect of chemotherapy, leading to enhanced cytotoxicity in target cells and ...
10